Pacira BioSciences, Inc. (PCRX:NASDAQ) closed at $36.49 on November 10, 2026, up 0.08% on the day. The stock trades 0.5% below its 52-week high of $36.67 and 94.1% above its 52-week low of $18.80. Over the past year, it gained 58.0%. Pacira BioSciences, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 10, 2025, PCRX closed higher on 141 days (56%). Its best day was October 8, 2026 (+44.40%) and its worst was August 5, 2026 (-9.96%). The stock moved 10% or more in a single session 1 time. It opened at least 5% above the previous day's high 1 time.
Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. The company develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. Its lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. The company also markets DepoCyt(e), a liposomal formulation of the chemotherapeutic agent cytarabine indicated for the intrathecal treatment of lymphomatous meningitis, a life-threatening complication of lymphoma, a cancer of the immune system. Its development pipeline comprises DepoTranexamic Acid, a long-acting local antifibrinolytic agent, which is in Phase II clinical development for the treatment or prevention of excessive blood loss during surgery by preventing the breakdown of a clot; and DepoMeloxicam, a long-acting non-steroidal anti-inflammatory drug, which is in preclinical development for the treatment of acute postsurgical pain. The company was formerly k...
Find more stocks like PCRX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.